JIM CRAMERSmartsheet, Prudential, Salesforce.com: 'Mad Money' Lightning RoundBy Scott RuttJul 10, 2018 6:34 AM EDT
PRESS RELEASESEditas Medicine Reports On Recent Progress At J.P. Morgan Healthcare ConferenceBy GlobeNewswireJan 13, 2020 9:00 AM EST
JIM CRAMERSmartsheet, Prudential, Salesforce.com: 'Mad Money' Lightning RoundBy Scott RuttJul 10, 2018 6:34 AM EDT
JIM CRAMERThese Stocks Are Still Bargains: Cramer's 'Mad Money' RecapBy Scott RuttJul 10, 2018 6:29 AM EDT
JIM CRAMERBox, Applied Materials, Goodyear: 'Mad Money' Lightning RoundBy Scott RuttMay 2, 2018 6:29 AM EDT
STOCKSAxovant Rises After Tuesday's Plunge - Biotech MoversBy Armie Margaret LeeSep 27, 2017 9:46 AM EDT
JIM CRAMERWhat to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)By Scott RuttJul 10, 2017 6:20 AM EDT
STOCKSAllergan, Editas Sign Gene-Editing Pact for Rare Eye DiseasesBy Adam FeuersteinMar 14, 2017 9:59 AM EDT
HEALTHBiotech Premarket Movers: Editas, Amphastar, Aratana, PaciraBy Armie Margaret LeeMar 14, 2017 9:26 AM EDT
STOCKSWhat Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017By Adam FeuersteinJan 5, 2017 6:21 AM EST
STOCKSAlphabet loses yet another exec from its 'other bets' divisionBy Jaewon KangAug 11, 2016 12:40 PM EDT
STOCKSAnalysts' Actions -- Coach, SunPower, Wayfair, Yelp and MoreBy TheStreet StaffAug 10, 2016 8:15 AM EDT
OPINION13 companies to watch from MIT's smart 50 list, including 4 buysBy Robert WassermanJul 21, 2016 7:48 AM EDT
OPINIONShould you place an early bet on the ipo of gene-splicing pioneer intellia?By Chiradeep BasuMallickMay 2, 2016 1:29 PM EDT
STOCKSGilead, Biogen troubles show why strong drug patents are vital By Adam FeuersteinMar 25, 2016 10:30 AM EDT
